The ubiquitin-proteasome pathway and proteasome inhibitors

被引:247
作者
Myung, J
Kim, KB
Crews, CM [1 ]
机构
[1] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA
[2] Yale Univ, Dept Pharmacol, New Haven, CT 06520 USA
关键词
ubiquitin-proteasome pathway; protein degradation; proteasome inhibitor; natural product;
D O I
10.1002/med.1009.abs
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The ubiquitin-proteasome pathway has emerged as a central player in the regulation of several diverse cellular processes. Here. we describe the important components of this complex biochemical machinery as well as several important cellular substrates targeted by this pathway and examples of human diseases resulting from defects in various components of the ubiquitin-proteasome pathway. In addition, this review covers the chemistry of synthetic and natural proteasome inhibitors, emphasizing their mode of actions toward the 20S proteasome. Given the importance of proteasome-mediated protein degradation in various intracellular processes, inhibitors of this pathway will continue to serve as both molecular probes of major cellular networks as well as potential therapeutic agents for various human diseases. (C) 2001 John Wiley & Sons. Inc.
引用
收藏
页码:245 / 273
页数:29
相关论文
共 258 条
  • [1] beta-catenin is a target for the ubiquitin-proteasome pathway
    Aberle, H
    Bauer, A
    Stappert, J
    Kispert, A
    Kemler, R
    [J]. EMBO JOURNAL, 1997, 16 (13) : 3797 - 3804
  • [2] Adams J, 1999, CANCER RES, V59, P2615
  • [3] Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
    Adams, J
    Behnke, M
    Chen, SW
    Cruickshank, AA
    Dick, LR
    Grenier, L
    Klunder, JM
    Ma, YT
    Plamondon, L
    Stein, RL
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (04) : 333 - 338
  • [4] Proteasome inhibition: a new strategy in cancer treatment
    Adams, J
    Palombella, VJ
    Elliott, PJ
    [J]. INVESTIGATIONAL NEW DRUGS, 2000, 18 (02) : 109 - 121
  • [5] STIMULATION-DEPENDENT I-KAPPA-B-ALPHA PHOSPHORYLATION MARKS THE NF-KAPPA-B INHIBITOR FOR DEGRADATION VIA THE UBIQUITIN-PROTEASOME PATHWAY
    ALKALAY, I
    YARON, A
    HATZUBAI, A
    ORIAN, A
    CIECHANOVER, A
    BEN-NERIAH, Y
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) : 10599 - 10603
  • [6] TUMOR-INDUCTION BY ACTIVATED ABL INVOLVES TYROSINE PHOSPHORYLATION OF THE PRODUCT OF THE CBL ONCOGENE
    ANDONIOU, CE
    THIEN, CBF
    LANGDON, WY
    [J]. EMBO JOURNAL, 1994, 13 (19) : 4515 - 4523
  • [7] ANGELMAN H, 1965, DEV MED CHILD NEUROL, V7, P681
  • [8] Regulation of p53 stability
    Ashcroft, M
    Vousden, KH
    [J]. ONCOGENE, 1999, 18 (53) : 7637 - 7643
  • [9] NF-kappa B: Ten years after
    Baeuerle, PA
    Baltimore, D
    [J]. CELL, 1996, 87 (01) : 13 - 20
  • [10] BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141